Lymfoom geassocieerde studies

Open studies

Naam ZUMA-2 cohort 3
Titel A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
Status Open in AUMC (AMC), EMC & UMCG
Medicatie KTE-X19
Populatie r/r MCL BTKi-naive (i.e. Ibrutinib, Acalabrutinib)
Documenten Subject eligibility
Naam EPCORE DLBCL-1
Titel A randomized phase 3 trial of subcutaneous epcoritamab versus investigator choice chemotherapy (R-Gem/Ox or R-benda) in relapsed/ refractory DLBCL
Status Open
Informatie

rr DLBCL (de novo or tFL); HGBCL (de novo or tFL); FL grade 3b.
After or not eligible for ASCT (due to age, performance, co-morbidity or insufficient response) 

Deelnemers

Open at Erasmus MC (p.lugtenburg@erasmusmc.nl)
The study will open soon in 11 other HOVON centers

Documenten Eligibility checklist
Naam Mangrove studie (Beigene-3111-306)
Titel A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Status Open
Deelnemers

Erasmus MC Rotterdam – J Doorduijn
Albert Schweitzer Ziekenhuis Dordrecht – E de Jongh
Hagaziekenhuis den Haag – L Bohmer
ADRZ Goes – Y Bilgin
UMCG Groningen – T v Meerten
Spaarnegasthuis Hoofddorp –A Beeker

Documenten In- en exclusiecriteria
Naam HD21
Titel Treatment optimization trial in the first line treatment of adv stage HL: comparison of 4-6 cycles of esc BEACOPP with 4-6 cycles of BrECADD
Status Open
Deelnemers AmsterdamUMC - VUmc - JM Zijlstra
MeanderMC – JC Regelink
Jeroen Bosch ziekenhuis- H Pruijt
ADR ziekenhuis Goes- S Kuipers
OLVG A’dam – A. Gerrits
WFG Hoorn- C Klerk
Haga ziekenhuis- L Bohmer
LUMC- H Veelken
Anthonius ziekenhuis- M Sohne
Documenten Flow + in- en exclusiecriteria
Protocol

 

Up